Stocks Pressured by US-China Trade Tensions

US stock indexes experienced downward pressure due to renewed concerns about US-China trade relations, triggered by comments from Treasury Secretary Bessent and accusations from President Trump regarding tariff agreements. Economic data presented a mixed picture, with personal income rising more than expected and the core PCE price index easing to a four-year low, offset by a weaker-than-expected Chicago PMI. While Q1 earnings season showed strong results with 77% of S&P 500 companies beating estimates, full-year 2025 corporate profit forecasts have been revised downward.

Analysis

US equity markets are experiencing downward pressure, with the S&P 500, Dow Jones Industrials, and Nasdaq 100 indices declining by -0.25%, -0.11%, and -0.25% respectively, primarily due to escalating concerns over US-China trade policy following Treasury Secretary Bessent's remarks about stalled talks and President Trump's accusations of China violating tariff agreements. This negative sentiment partially overshadows some supportive domestic economic data, including a +0.8% month-over-month rise in April personal income, the largest increase in 15 months, and an easing of the April core PCE price index to +2.5% year-over-year, its slowest pace in over four years, a potentially dovish signal for Federal Reserve policy. However, the US May Chicago PMI unexpectedly fell by 4.1 points to 40.5, weaker than expectations of an increase to 45.0. While Q1 earnings season has been robust, with 77% of S&P 500 companies surpassing estimates and achieving an average earnings growth of +13.1%, significantly above the +6.6% anticipated pre-season, the outlook for full-year 2025 corporate profits for the S&P 500 has been revised downwards to +9.4% from an earlier +12.5% forecast in January, signaling potential headwinds. Dallas Fed President Logan’s comments suggest the Fed may maintain current interest rates for "quite some time," with markets currently pricing only a 2% chance of a rate cut at the June FOMC meeting. Specific company news highlights these broader uncertainties and individual challenges: Marvell Technology (MRVL) declined over -5% on a weaker Q2 adjusted gross margin forecast, Regeneron Pharmaceuticals (REGN) dropped over -17% due to disappointing late-stage trial results for its COPD drug, and The Gap (GAP) fell over -20% after forecasting flat Q2 net sales and warning of a potential $250 million to $300 million earnings hit from tariffs. Conversely, Ulta Beauty (ULTA) surged over +12% on strong Q1 EPS of $6.70 and raised 2026 EPS guidance, and Zscaler (ZS) rose over +8% after reporting Q3 revenue of $678.0 million and raising its full-year revenue forecast.

Key Decisions for Investors

• Investors should closely monitor US-China trade developments, as these remain a key driver of market volatility and directly impact companies with significant China exposure, such as The Gap (GAP) which warned of substantial tariff-related earnings impact.
• Maintain a cautious stance on expecting imminent Federal Reserve rate cuts; while the core PCE price index (+2.5% y/y) has eased, strong personal income growth (+0.8% m/m) and cautious Fed commentary (Logan) suggest a patient policy approach.
• Scrutinize corporate forward guidance intensely, as the downward revision in full-year 2025 S&P 500 profit growth forecasts (to +9.4%) despite a strong Q1 earnings season underscores the importance of identifying companies with resilient business models and earnings power amidst macroeconomic uncertainties.
• Recognize the current market environment favors stock-specific analysis, given significant performance divergence such as Ulta Beauty's (ULTA) surge versus Regeneron's (REGN) sharp decline, necessitating careful evaluation of individual company fundamentals and catalysts.